Medicinal cannabis: Principal cannabinoids concentration and their stability evaluated by a high performance liquid chromatography coupled to diode array and quadrupole time of flight mass spectrometry method

Journal of Pharmaceutical and Biomedical Analysis

Volumn 128, Issue , 2016, Pages 201-209

  Citti, Cinzia ^a   Ciccarella, Giuseppe ^a   Braghiroli, Daniela ^b   Parenti, Carlo ^b   Vandelli, Maria Angela ^b   Cannazza, Giuseppe ^a,b  

^a UNIVERSITY OF SALENTO   (Italy)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Cannabinoids extraction; Cannabinoids stability; Gas chromatography; Liquid chromatography; Mass spectrometry; Medicinal cannabis

Indexed keywords

ALCOHOL; CANNABINOID; MEDICAL CANNABIS; OLIVE OIL; CANNABIS; PLANT EXTRACT; SOLVENT;

ARTICLE; DRUG ISOLATION; DRUG STABILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; PRIORITY JOURNAL; QUADRUPOLE MASS SPECTROMETRY; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; SUPERCRITICAL FLUID EXTRACTION; THERMOSTABILITY; CHEMISTRY; ELECTROSPRAY MASS SPECTROMETRY; LIMIT OF DETECTION; MASS FRAGMENTOGRAPHY; MASS SPECTROMETRY; REPRODUCIBILITY;

CANNABINOIDS; CANNABIS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG STABILITY; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; LIMIT OF DETECTION; MASS SPECTROMETRY; MEDICAL MARIJUANA; PLANT EXTRACTS; REPRODUCIBILITY OF RESULTS; SOLVENTS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION;

EID: 84971441343     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2016.05.033     Document Type: Article

References (30)

1. Ware M.A., Muller-Vahl K.R., Abrams D., Grotenhermen F., Hazekamp A. The medicinal use of cannabis and cannabinoids-an international cross-sectional survey on administration forms. J. Psychoact. Drugs 2013, 45:199-210.
2. McPartland J.M., Russo E.B. Cannabis is more than simply δ9-tetrahydrocannabinol. Psychopharmacology 2003, 165:431-432.
3. Scott K.S., Kacinko S.L., Presley B.C., Logan B.K., Gurney S.M.R. Pharmacology toxicology, and adverse effects of synthetic cannabinoid drugs. Forensic Sci. Rev. 2014, 26:53-78.
4. Robson P., House H., Makela P., Aram J., Wade D.T. A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clin. Rehabil. 2003, 17:21-29.
5. Robson P., Ho M., Jubb R.W., McCabe C.S., Blake D.R. Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology 2006, 45:50-52.
6. Brust J.C.M., Fife T., Bronstein J., Youssof S., Gronseth G., Gloss D., Koppel B.S. Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders. Neurology 2014, 82:1556-1563.
7. Franson K.L., Nussbaum A.M., Wang S., Borgelt L.M. The pharmacologic and clinical effects of medical cannabis. Pharmacotherapy 2013, 33:195-209.
8. Wolff R.F., Deshpande S., Di Nisio M., Duffy S., Hernandez A.V., Keurentjes J.C., Lang S., Misso K., Ryder S., Schmidlkofer S., Westwood M., Kleijnen J., Whiting P.F. Cannabinoids for medical use: a systematic review and meta-analysis. J. Am. Med. Assoc. 2015, 313:2456-2473.
9. Russo E.B. Cannabinoids in the management of difficult to treat pain. Ther. Clin. Risk Manag. 2008, 4:245-259.
10. Russo E.B. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br. J. Pharmacol. 2011, 163:1344-1364.
11. Müller-Vahl K.R., Grotenhermen F. The therapeutic potential of cannabis and cannabinoids. Dtsch. Arztebl. Int. 2012, 109:495-501.
12. Cely W., Turkanis S.A., Karler R. The anticonvulsant activity of cannabidiol and cannabinol. Life Sci. 1973, 13:1527-1531.
13. Vassar H.B., Knobloch L.C., Sofia R.D. Comparative analgesic activity of various naturally occurring cannabinoids in mice and rats. Psyehopharmacologia (Berl.) 1975, 40:285-295.
14. Ulrich-Merzenich G., Wagner H. Synergy research: approaching a new generation of phytopharmaceuticals. Phytomedicine 2009, 16:97-110.
15. Shirakawa I., Kasinski N., Pfeferman A., Carlini E.A., Karniol I.G. Cannabidiol interferes with the effects of δ9-tetrahydrocannabinol in man. Eur. J. Pharmacol. 1974, 28:172-177.
16. Misawa K., Yamamoto I., Watanabe K., Takeda S. Cannabidiolic acid as a selective cyclooxygenase-2 inhibitory component in cannabis. Drug Metab. Dispos. 2008, 39:1917-1921.
17. Mehmedic Z., Murphy T.P., ElSohly M.A., Ross S.A. GC-MS analysis of the total δ9-THC content of both drug- and fiber-type cannabis seeds. J. Anal. Toxicol. 2000, 24:715-717.
18. Verpoorte R., Raharjo T.J. Methods for the analysis of cannabinoids in biological materials: a review. Phytochem. Anal. 2004, 15:79-94.
19. Hazekamp A., Romano L. Cannabis oil: chemical evaluation of an upcoming cannabis-based medicine. Cannabinoids 2013, 1:1-11.
20. Tedeschi L., Frison G., Castagna F., Ferrara S.D. Solid-phase extraction and HPLC-UV confirmation of drugs of abuse in urine. J. Anal. Toxicol. 1992, 16:217-222.
21. Szwarc E., Tracqui A., Ludes B., Jamey C. Determination of cannabinoids in whole blood by UPLC-MS-MS. J. Anal. Toxicol. 2012, 36:280-287.
22. Scholera A., Drewe J., Grauwilera S.B. Development of a LC/MS/MS method for the analysis of cannabinoids in human EDTA-plasma and urine after small doses of Cannabis sativa extracts. J. Chromatogr. B 2007, 850:515-522.
23. Heerdink E.R., Hazekamp A. The prevalence and incidence of medicinal cannabis on prescription in The Netherlands. Eur. J. Clin. Pharmacol. 2013, 69:1575-1580.
24. Ministero della Salute, GU Serie Generale, n. 279 del 30-11-2015.
25. Russo E.B., McPartland J.M. Cannabis and cannabis extracts: greater than the sum of their parts?. J. Cannabis Ther. 2001, 1:103-132.
26. EMEA ICH Topic Q2(R1) Validation of Analytical Procedures: Text and Methodology (2006).
27. International Conference on Harmonization of Technical Requirements for the Registration of Pharmaceuticals for Human Use (ICH), Guideline Q2(R1)-Validation of Analytical Procedures: Text and Methodology, ICH Secretariat, c/o IFPMA, Geneva (2005) p. 1.
28. Wingard D.W., Masoud A.N. High performance liquid chromatography with electrochemical detection. 1: Separation of cannabis constituents and quantitation of δ9 tetrahydrocannabinol. J. High Resolut. Chromatogr. 1979, 2:118-122.
29. Wong J.C., Sabri A., Fischer P.M., Barrett D.A., Constantinescu C.S., Gershkovich P., Zgair A. Development of a simple and sensitive HPLC-UV method for the simultaneous determination of cannabidiol and δ(9)-tetrahydrocannabinol in rat plasma. J. Pharm. Biomed. Anal. 2015, 114:145-151.
30. H. Perrotin-Brunel, Dissertation: sustainable production of cannabinoids with supercritical carbon dioxide technologies (2011) uuid: http://c1b4471f-ea42-47cb-a230-5555d268fb4c.